Introduction
============

Bleeding from gastroesophageal varices is the most common life-threatening complication in patients with cirrhosis, being associated with mortality rates from 10 % to 50 % per episode [@JR1465-1] [@JR1465-2] . More than half of patients who survive the first episode suffer from recurrent bleeding within 1 year [@JR1465-3] [@JR1465-4] . Management of acute variceal bleeding (AVB) remains a clinical challenge with high mortality, in spite of standardization in supportive and new therapeutic treatments in the last two decades [@JR1465-5] .

A beneficial effect on survival has been observed in parallel with introduction of drugs that are capable of decreasing portal pressure, optimization of endoscopic therapy, and use of antibiotics and interventional radiologic procedures. During the same period, the 6-week mortality rate has decreased from approximately 40 % to 15 % [@JR1465-5] [@JR1465-6] .

Although overall survival has improved in recent years, mortality is still closely related to failure to control the initial bleeding or early rebleeding, which occurs in up to 30 % to 40 % of patients within the first 5 days after the index bleeding episode [@JR1465-5] [@JR1465-6] . As a consequence, many patients with cirrhosis and AVB still suffer from failure to control bleeding and most of them die very early [@JR1465-2] . Therapeutic options include vasoactive drugs such as somatostatin, octreotide, and terlipressin; endoscopic treatments such as sclerotherapy and band ligation; and most recently, radiologic interventions, such as early-TIPS (transjugular intrahepatic portosystemic shunt) placement. Therefore, the goal of this study was to evaluate the efficacy and safety of the most-used endoscopic treatments for controlling AVB.

Methods
=======

A meta-analysis and systematic review of published randomized controlled trials (RCTs) were carried out.

Search strategy
---------------

Medline (PubMed), Embase, Cochrane library and manual searches were combined and last performed on 16 March 2018. Key search terms were "esophageal and gastric varices," "esophageal varices," "esophageal varix," "oesophageal varices," "oesophageal varix," "esophagogastric varices," "esophagogastric varix," "gastroesophageal varices," "gastroesophageal varix," "oesophagogastric varices," "oesophagogastric varix," "oesophago-gastric varices," "oesophago-gastric varix," "esophago-gastric varices," "esophago-gastric varix," upper gastrointestinal bleeding," "bleeding, upper gastrointestinal," "upper digestive haemorrhage," "upper digestive hemorrhage," "upperdigestive tract haemorrhage," "upper digestive tract hemorrhage," "uppergastrointestinal haemorrhage," "upper gastrointestinal hemorrhage, "upper gastrointestinal tract bleeding," "variceal bleeding," "esophagus varices bleeding," "esophagus bleeding varix," "esophagus varices haemorrhage," "esophagus varices hemorrhage," and "esophagus varix bleeding". MeSH terms and free-text terms, as well as variation of root words were searched. Terms were combined within each database. The study has been registered in PROSPERO database under code CRD42017058139.

Criteria for inclusion and exclusion of studies
-----------------------------------------------

Only RCTs were included. To reduce the risk of bias, strict inclusion and exclusion criteria were defined prior to literature search. To be considered, a study had to include patients exclusively with cirrhosis, patients with acute variceal bleeding, have more than 10 patients in each arm, include only adults, and include treatments performed in the first 24 to 48 hours after bleeding. Studies were excluded if they included patients with hepatocellular carcinoma or other malignancies, use of portocaval shunts or esophageal resection, recent use of balloon tamponade as first bleeding control measure, placebo or elective treatment in one study arm. When two publications existed covering the same study population, only the most recent was taken into account.

Endpoints
---------

Endpoints were defined prior to the beginning of the meta-analysis. Main endpoints were treatment efficacy for bleeding control and in-hospital mortality. Secondary endpoints were rate of rebleeding from active bleeders at initial endoscopy, rate of overall rebleeding, rate of overall mortality, and rate of adverse events (AEs) related to each treatment.

Data extraction and assessment of quality
-----------------------------------------

Two reviewers independently abstracted data from included articles (F.Q.O. and F.M.V.). Disagreements were resolved by consensus of all authors. Extracted information included patient population characteristics, intervention characteristics, comparator characteristics, outcomes assessed, and study quality. The latter used the framework suggested by the Cochrane Handbook for Systematic Reviews of Interventions (version 5·1·0), with evaluation of the following trial characteristics: random sequence generator method, concealment of treatment allocation, blinding of participants and personnel, blinding of outcome assessment, and for selective reporting [@JR1465-7] . Intention-to-treat analysis and the funding source of the studies were also assessed. The GRADE methodology [@JR1465-7] was used to define risk of bias for each of the outcomes that had available data.

Sources of support
------------------

This systematic review and meta-analysis was not supported by any grant.

Statistical analysis
--------------------

We performed direct random effects model meta-analyses of head-to-head comparisons for pooling effect sizes of reported comparisons and outcomes whenever enough data were provided in published studies. No data imputation was done, and studies not reporting information that allowed treatment-effect calculation were not included in the meta-analyses. Summary effect for binary outcomes was calculated from risk ratios. Heterogeneity was evaluated with the inconsistency test proposed by Higgins (I ^2^ ), where values below 25 % were considered as low heterogeneity, and above 75 %, high heterogeneity [@JR1465-8] [@JR1465-9] . Publication bias was assessed with funnel plots of comparisons with seven or more studies. Meta-analyses were carried out in Review Manager 5·3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). Prediction intervals were calculated with the Paule-Mandel estimator for tau squared and the Hartung-Knapp adjustment for random effects model. Prediction interval calculations were done with the software "R" (v 3.5.0) and package "Meta" (v 4.9 -- 4) [@JR1465-10] .

Results
=======

Studies selection
-----------------

A total of 8382 citations were screened, of them 6691 were evaluated after duplicates were removed ( [Fig. 1](#FI1465-1){ref-type="fig"} ). Of these, 69 were selected for full-text evaluation. Among them, only 36 randomized trials [@JR1465-11] [@JR1465-12] [@JR1465-13] [@JR1465-14] [@JR1465-15] [@JR1465-16] [@JR1465-17] [@JR1465-18] [@JR1465-19] [@JR1465-20] [@JR1465-21] [@JR1465-22] [@JR1465-23] [@JR1465-24] [@JR1465-25] [@JR1465-26] [@JR1465-27] [@JR1465-28] [@JR1465-29] [@JR1465-30] [@JR1465-31] [@JR1465-32] [@JR1465-33] [@JR1465-34] [@JR1465-35] [@JR1465-36] [@JR1465-37] [@JR1465-38] [@JR1465-39] [@JR1465-40] [@JR1465-41] [@JR1465-42] [@JR1465-43] [@JR1465-44] [@JR1465-45] [@JR1465-46] were identified that fulfilled the inclusion criteria ( [Table 1](#TB1465-1){ref-type="table"} ): seven studies compared sclerotherapy with vasoactive drugs (two studies with somatostatin, three studies with octreotide, one with terlipressin and one with vasopressin plus nitroglycerin); two studies compared ligation with vasoactive drugs (one with octreotide and one with somatostatin); one study compared ligation with cyanoacrylate injection; 10 studies compared sclerotherapy with ligation; seven studies compared sclerotherapy with the combination of sclerotherapy and vasoactive drugs (six with octreotide and one with somatostatin); five studies compared ligation with sclerotherapy and ligation; two studies compared ligation with ligation and vasoactive drugs (one with somatostatin and with octreotide); one study compared sclerotherapy and octreotide with octreotide alone; and one study compared ligation and octreotide with octreotide alone.

![ Study selection flowchart.](10-1055-a-0901-7146-i1465ei1){#FI1465-1}

###### Demographic data from included studies.

  Author (year)                                     Patients, n \[a/b\]   Mean age, years   Men, n %   Main cause of cirrhosis, n \[a/b\]   Child-pugh class c % \[a/b\]   Active bleeding % \[a/b\]   Follow-up for initial control of bleeding (hours)
  ------------------------------------------------- --------------------- ----------------- ---------- ------------------------------------ ------------------------------ --------------------------- ---------------------------------------------------
  **Intervention axb**                                                                                                                                                                                 
  **Sclerotherapy x VP + NG**                                                                                                                                                                          
  Westaby (1989)                                     33/31                54.2              56.3       Alcohol 13/alcohol 22                36/32                          100/100                      12
  **Sclerotherapy x somatostatin**                                                                                                                                                                     
  Shields (1992)                                     41/39                58                67.5       Alcohol 26/alcohol 28                41/64                           61/69                      120
  Planas (1994)                                      35/35                57                71.4       Alcohol 28/alcohol 22                34/34                           48.5/51.4                   48
  **Sclerotherapy x octreotide**                                                                                                                                                                       
  Sung (1993)                                        49/49                55.7              84.7       HBV 32/HBV 36                        42/43                           37/51                       48
  Sivri (2000)                                       36/30                47                24.2       Viral 8/viral 14                     53/55                          100/100                       6
  Bildozola (2000)                                   37/39                52.6              78.9       Alcohol 27/alcohol 28                8/13                            48.6/38.5                   12
  **Sclerotherapy x terlipressin**                                                                                                                                                                     
  Escorsell (2000)                                  114/105               55.5              72.1       Alcohol 47/alcohol 41                31/32                           42.9/35.2                   48
  **Sclerotherapy x sclerotherapy + octreotide**                                                                                                                                                       
  Besson (1995)                                     101/98                56                76.4       Alcohol 93/alcohol 89                46/26                           46.5/428                    24
  Shiha (1996)                                       96/93                49.6              81.5       HCV 45/HCV 44                        12/15                          100/100                     168
  Faraoqi (2000)                                     69/72                                                                                                                 100/100                     Not clearly stated
  Zuberi (2000)                                      35/35                38.5              80.0       HBV 28/HBV 26                         0/0                           100/100                      24
  Shah (2005)                                        54/51                49.8              64.8       Viral 52/viral 49                    26/21                           44.4/45                    Not clearly stated
  Morales (2007)                                     28/40                51.8              66.2       HCV 14/HCV + alcohol 11              36/60                           46/65                      Not clearly stated
  **Sclerotherapy x sclerotherapy + somatostain**                                                                                                                                                      
  Avgerinos (1997)                                  101/104               58.6              70.7       Alcohol 59/alcohol 61                28/25                           40.3/26.7                  Not clearly stated
  **Octreotide + sclerotherapy x octreotide**                                                                                                                                                          
  Patsanas (2002)                                    15/15                51                70.0       Alcohol 8/viral 5                    60/53                           33/43                      120
  **Sclerotherapy x ligation**                                                                                                                                                                         
  Stiegmann (1992)                                   65/64                52.0              80.6       Alcohol 52/alcohol 53                20/19                           20/22                        8
  Laine (1993)                                       38/39                46.0              75.3       Alcohol 30/alcohol 31                12,8/34,2                       23/24                      Not clearly stated
  Gimson (1993)                                      49/54                51.4              55.3       Alcohol 24/alcohol 25                24/28                           23/39                       12
  Lo (1995)                                          59/61                55.5              80.8       Viral 43/viral 41                    47/49                           25/29                       72
  Hou (1995)                                         67/67                60.6              79.9       Viral 47/viral 43                    34/43                           23/29.8                     24
  Lo (1997)                                          34/37                54.0              86.1       HCV 11 + alcohol 11/HBV 15           59/59                          100/100                      72
  Shafqat (1998)                                     30/28                52.0              63.8       HCV 21/HCV 18                        13/11                           93/86                       12
  De la Peña (1999)                                  46/42                59.0              72.7       Alcohol 29/alcohol 29                28/24                           47.8/42.8                  Not clearly stated
  Luz (2011)                                         50/50                52.3              72.0       Alcohol 19 + virus 19/alcohol 17     40/30                           10/20                      120
  Sahu (2014)                                       103/111                                                                                                                                            Not clearly stated
  **Ligation x octreotide**                                                                                                                                                                            
  Ximing (2013)                                                                                                                                                                                        Not clearly stated
  **Ligation x somatostatin**                                                                                                                                                                          
  Chen (2006)                                        62/63                53.2              76.0       Alcohol 24/alcohol 29                29/28                           27.4/20.6                   48
  **Ligation x cyanoacrylate injection**                                                                                                                                                               
  Ljubicic (2011)                                    21/22                58                72.1       Alcohol/ alcohol                     19/41                           52.4/90.9                   24
  **Ligation x ligation + sclerotherapy**                                                                                                                                                              
  Laine (1996)                                       20/21                47                73.2       Alcohol 16/alcohol 15                45/43                           20/19                      Not clearly stated
  Saeed (1997)                                       25/22                53.1              91.5       Alcohol 22/alcohol 16                16/41                           28/18                      Not clearly stated
  Al traif (1999)                                    31/29                48.8              61.7       HCV 10/HCV 14                        32/17                           22.5/31                    Not clearly stated
  Djurdjevic (1999)                                  51/52                55.6              61.2       Alcohol 25/alcohol 28                23/19                           23.5/19,2                  Not clearly stated
  Mansour (2017)                                     60/60                 0.0              65.0       HCV 52/HCV 52                        53/40                                                       48
  **Ligation + octreotide x octreotide**                                                                                                                                                               
  Liu (2009)                                         51/50                41                81.2                                            55/48                           35.2/34                     72
  **Ligation x ligation + somatostatin**                                                                                                                                                               
  Sarin (2008)                                       24/23                43.6              74.0                                                                            40.0                       Not clearly stated
  **Ligation x ligation + octreotide**                                                                                                                                                                 
  Sung (1995)                                        47/47                57.0              71.3       Hepatitis 29/hepatitis 27            40.4/42.6                       44.7/34.0                   24

Studies characteristics
-----------------------

Only 32 RCTs had been published as full papers. Four trials were published as abstracts [@JR1465-32] [@JR1465-40] [@JR1465-44] [@JR1465-45] . In six studies [@JR1465-11] [@JR1465-23] [@JR1465-24] [@JR1465-31] [@JR1465-32] [@JR1465-35] , patients were included only if they had ongoing bleeding at time of initial endoscopy. Alcoholic cirrhosis was the predominant cause of portal hypertension in 18 studies. In contrast, cirrhosis due to viral hepatitis infection was the leading cause in 13 studies (patients from Asia, Brazil, and the Middle East). Otherwise, baseline characteristics of the study populations, such as gender ratio, Child-Pugh class or mean age, were comparable ( [Table 1](#TB1465-1){ref-type="table"} ). Only 11 of the 36 trials described separately the rebleeding rate of the different treatment modalities in active bleeders at the time of endoscopy, i. e., 25 studies analyzed together active and non-active bleeders ( **Supplementary Table 1 -- Supporting Information** ).

Risk of bias within trials
--------------------------

The included trials had risk of bias evaluated according to the Cochrane recommendations for meta-analyses and systematic reviews ( [Fig. 2](#FI1465-2){ref-type="fig"} ). None of the included trials were placebo-controlled. The randomization-method of the majority of the trials was computer-generated random sequences, with only four trials (abstracts) having no information about randomization. Eighteen trials had low risk for concealment of treatment allocation. Blinding of outcome assessment was not stated in any of the peer-reviewed articles.

![ Risk of bias assessment of included studies. Green circles: low risk of bias for a given quality assessment domain; blue circles: unclear risk of bias for a given quality assessment domain; red circles: high risk of bias for a given quality assessment domain.](10-1055-a-0901-7146-i1465ei2){#FI1465-2}

Prediction intervals for random effects meta-analyses are presented in [Table 2](#TB1465-2){ref-type="table"} .

###### Prediction intervals for random-effects models.

  Comparison                                 Outcome                           Prediction interval   Meta-analysis and prediction interval interpretation
  ------------------------------------------ --------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Ligation x sclerotherapy**                                                                       
                                             Efficacy of bleeding control      0.91 to 1.29          Random effects meta-analysis statistically signiffican but prediction interval indicating uncertainty on true effect size and direction
                                             Overall rebleeding                0.25 to 1.99          Random effects meta-analysis statistically signiffican but prediction interval indicating uncertainty on true effect size and direction
                                             In-hospital mortality             Zero to infinity      No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating complete uncertainty on true effect size and direction
                                             Overall mortality                 0.33 to 1.57          Random effects meta-analysis statistically signiffican but prediction interval indicating uncertainty on true effect size and direction
                                             Complications                     0.18 to 0.47          Random effects meta-analysis statistically signifficant and prediction interval indicating low uncertainty on true effect size and no uncertainty on true effect direction
  **Sclerotherapy x drug**                                                                           
                                             Efficacy of bleeding control      0.99 to 1.17          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction
                                             Overall rebleeding                0.71 to 1.06          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction
                                             Rebleeding from active bleeders   0.92 to 1.48          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating some uncertainty on true effect size and direction
                                             In-hospital mortality             0.43 to 1.42          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction
                                             Overall mortality                 0.41 to 1.49          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating some uncertainty on true effect size and direction
                                             Complications                     1.34 to 3.29          Random effects meta-analysis statistically signifficant and prediction interval indicating some uncertainty on true effect size and no uncertainty on true effect direction
  **Sclerotherapy + drug x sclerotherapy**                                                           
                                             Efficacy of bleeding Control      1.04 to 1.31          Random effects meta-analysis statistically signifficant and prediction interval indicating low uncertainty on true effect size and no uncertainty on true effect direction
                                             Overall rebleeding                0.08 to 1.40          Random effects meta-analysis statistically signifficant and prediction interval indicating some uncertainty on true effect size and direction
                                             Rebleeding from active bleeders   0.02 to 3.45          Random effects meta-analysis statistically signiffican but prediction interval indicating uncertainty on true effect size and direction
                                             In-hospital mortality             0.52 to 1.32          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction
                                             Overall mortality                 0.64 to 1.28          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction
  **Ligation x ligation + sclerotherapy**                                                            
                                             Efficacy of bleeding control      0.70 to 1.45          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating high uncertainty on true effect size and direction
                                             Overall rebleeding                0.60 to 1.48          No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating some uncertainty on true effect size and direction
                                             In-hospital mortality             0.04 to 13.65         No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating high uncertainty on true effect size and direction
                                             Overall mortality                 0.06 to 14.32         No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating high uncertainty on true effect size and direction
                                             Complications                     0.30 to 0.86          Random effects meta-analysis statistically signifficant and prediction interval indicating low uncertainty on true effect size and no uncertainty on true effect direction
  **Ligation x drug**                                                                                
                                             Efficacy of bleeding control      0.98 to 1.88          Random effects meta-analysis statistically signifficant and prediction interval indicating some uncertainty on true effect size and little uncertainty on true effect direction
                                             Overall rebleeding                Zero to infinity      No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating complete uncertainty on true effect size and direction
                                             Overall mortality                 Zero to infinity      No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating complete uncertainty on true effect size and direction
  **Ligation x ligation + drug**                                                                     
                                             Overall rebleeding                Zero to infinity      No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating complete uncertainty on true effect size and direction
                                             Overall mortality                 0.15 to 26.64         No statistically significant differences in random-effects meta-analysis estimate and prediction interval indicating low uncertainty on true effect size and direction

Risk of bias across trials
--------------------------

With respect to risk of publication bias, funnel plots were generally symmetrical, which indicates a low probability of publication bias in the present systematic review.

Comparison of sclerotherapy with vasoactive medications
-------------------------------------------------------

Sclerotherapy was compared to somatostatin, octreotide, and vasopressin plus nitroglycerin in seven trials. The rate of complications was significantly higher with sclerotherapy (6 trials; relative risk \[RR\] 2.10; 95 % confidence interval \[CI\] 1.52 -- 2.90; *P*  \< 0.00001; I ^2^  = 0 %) when compared to vasoactive drug alone. There was no significant difference in the other analyzed outcomes. The studies by Planas and Escorsell had no specific description of in-hospital mortality, so they were not included in this analysis.

In patients with active bleeding at endoscopy, sclerotherapy was needed in 17 patients to achieve active bleeding control in one of them when compared to vasoactive drug alone (number needed to treat \[NNT\] 17, I ^2^  = 0 %, *P*  \< 0.05).

Comparison of ligation with vasoactive medications
--------------------------------------------------

Only two trials [@JR1465-38] [@JR1465-44] compared ligation with vasoactive medications (somatostatin and octreotide). However, the study by Ximing was published as an abstract and did not have enough information to be included in the analysis.

Comparison of sclerotherapy with ligation
-----------------------------------------

Ligation was associated with significant improvement in bleeding control (10 trials; RR 1.08; CI 1.02 -- 1.15; *P*  = 0.01; I ^2^  = 49 %) compared to sclerotherapy ( [Fig. 3](#FI1465-3){ref-type="fig"} ). The heterogeneity was potentially explained by the differences in two identified subgroups: one formed by Lo [@JR1465-19] , Hou [@JR1465-21] , Lo [@JR1465-24] , Squafat [@JR1465-27] and de la Peña [@JR1465-29] (mostly Asian studies) in which ligation was clearly superior to sclerotherapy and another group of five trials (mostly Western trials) in which both techniques had similar results.

![ Forest plot of risk ratio for efficacy of bleeding control with ligation versus sclerotherapy.](10-1055-a-0901-7146-i1465ei3){#FI1465-3}

Risk of overall rebleeding was statistically significantly higher (10 trials; RR 1.41 95 % CI 1.03 -- 1.94; *P*  = 0.03; I ^2^  = 62 %) with sclerotherapy than with ligation. The high heterogeneity was explained by the same reasons as mentioned above.

Overall mortality was 38 % higher in patients treated with sclerotherapy compared to ligation (9 trials; RR 0.72 95 % CI 0.54 -- 0.97; *P*  = 0.03; I ^2^  = 35 %) ( [Fig. 4](#FI1465-4){ref-type="fig"} ). Overall mortality was not reported in the study by Laine et al [@JR1465-14] .

![ Forest plot of risk ratio for overall mortality with ligation versus sclerotherapy.](10-1055-a-0901-7146-i1465ei4){#FI1465-4}

Rebleeding rate from active bleeders (only 1 trial) could not generate meta-analysis. In-hospital mortality analysis (only 3 trials) had not shown statistical difference.

The rate of complications was significantly lower with ligation (8 trials; RR 0.29 95 %CI 0.20 -- 0.44; *P*  \< 0.00001; I ^2^  = 0 %) when compared to sclerotherapy.

Comparison of sclerotherapy and vasoactive medications with sclerotherapy alone
-------------------------------------------------------------------------------

Efficacy of bleeding control was 17 % higher with the combination of sclerotherapy and vasoactive drugs in comparison to sclerotherapy alone (7 trials; RR of 1.17; 95 % CI 1.10 -- 1.25; *P*  \< 0.00001; I ^2^  = 25 %) ( [Fig. 5](#FI1465-5){ref-type="fig"} ).

![ Forest plot of risk ratio for efficacy of bleeding control with sclerotherapy and vasoactive drug versus sclerotherapy alone.](10-1055-a-0901-7146-i1465ei5){#FI1465-5}

Overall rebleeding was 66 % lower (6 trials, RR 0.34; 95 % CI 0.19 -- 0.61; *P*  = 0.0003; I ^2^  = 42 %) with the association of sclerotherapy plus vasoactive drug compared to sclerotherapy alone ( [Fig. 6](#FI1465-6){ref-type="fig"} ).

![ Forest plot of risk ratio for overall rebleeding with sclerotherapy and vasoactive drug versus sclerotherapy alone.](10-1055-a-0901-7146-i1465ei6){#FI1465-6}

Risk of rebleeding from active bleeders at initial endoscopy was 73 % lower (4 trials; RR 0.27; 0.12 -- 0.60; *P*  = 0.001; I ^2^  = 35 %) with the combination of sclerotherapy and vasoactive drugs compared to sclerotherapy alone ( [Fig. 7](#FI1465-7){ref-type="fig"} ).

![ Forest plot of risk ratio for rebleeding from active bleeders comparing sclerotherapy and vasoactive drug versus sclerotherapy alone.](10-1055-a-0901-7146-i1465ei7){#FI1465-7}

In-hospital mortality and overall mortality did not show difference in effect.

Combining sclerotherapy with vasoactive drug in seven patients resulted in control of active bleeding and reduced risk of rebleeding in one patient when compared to sclerotherapy alone (NNT 7, I ^2^  = 0 %, *P*  \< 0.05) . In addition, the combination of sclerotherapy with vasoactive drug was needed in six patients to reduce rebleeding from active bleeders in one of them when compared to sclerotherapy alone (NNT -- 6, I ^2^  = 0 %, *P*  \< 0.05).

Comparison of ligation with the combination of ligation and sclerotherapy
-------------------------------------------------------------------------

Five trials [@JR1465-22] [@JR1465-26] [@JR1465-28] [@JR1465-30] [@JR1465-46] had evaluated ligation versus the combination of ligation and sclerotherapy. Risk of complications was significantly lower with ligation (5 trials, RR 0.58; 95 %CI 0.39 -- 0.88; *P*  = 0.01; I ^2^ 0 %) when compared to the combination of ligation and sclerotherapy. However, there were no statistically significant differences among the other analyzed outcomes.

Comparison of ligation with cyanoacrylate injection
---------------------------------------------------

Only one trial [@JR1465-42] evaluated ligation with cyanoacrylate injection and, therefore, could not generate meta-analysis. This trial showed no difference in efficacy of bleeding control, rebleeding rate, or mortality rate with cyanoacrylate injection compared with endoscopic ligation.

Comparison of ligation with ligation and vasoactive drugs
---------------------------------------------------------

Only two trials evaluated this treatment combination, one with somatostatin and other with octreotide [@JR1465-20] [@JR1465-39] . Among the outcomes analyzed, only overall rebleeding ( [Fig. 8](#FI1465-8){ref-type="fig"} ) and in-hospital mortality ( [Fig. 9](#FI1465-9){ref-type="fig"} ) generated meta-analysis, but with no significant statistical difference.

![ Forest plot of risk ratio for overall rebleeding with ligation alone versus ligation and vasoactive drug.](10-1055-a-0901-7146-i1465ei8){#FI1465-8}

![ Forest plot of risk ratio for in-hospital mortality with ligation alone versus ligation and vasoactive drug.](10-1055-a-0901-7146-i1465ei9){#FI1465-9}

Discussion
==========

Thirty-six trials, including 3593 patients, evaluated treatments for AVB control.

Among them, 10 trials compared sclerotherapy with ligation, favoring ligation in terms of efficacy of bleeding control, rebleeding, overall mortality, and rate of complications in a statistically significant fashion. However, this comparison showed a moderate heterogeneity.

The heterogeneity was potentially explained by the differences in two identified subgroups as stated above (results chapter): one formed mostly by Asian studies [@JR1465-19] [@JR1465-21] [@JR1465-24] [@JR1465-27] [@JR1465-29] in which ligation was clearly superior to sclerotherapy and another formed mostly by Western trials [@JR1465-13] [@JR1465-14] [@JR1465-15] [@JR1465-43] [@JR1465-45] in which both techniques had similar results. In the first subgroup of studies, the main cause of cirrhosis was viral and in three of five trials, the sclerosant used was tetradecyl sulfate with 50 % dextrose. In the second subgroup, the majority of patients had cirrhosis secondary to excessive alcohol intake and only one study used tetradecyl sulfate with 50 % dextrose as sclerosant. Moreover, the second subgroup had higher percentages of active bleeders at initial endoscopy in all ligation arms compared to the sclerotherapy arms, which was not noticed in the first subgroup of studies. Prevalence of Child-Pugh C patients was similar in both subgroups.

Although ligation currently is considered the gold standard endoscopic method compared to sclerotherapy, this meta-analysis could not demonstrate clearly the superiority of one technique over the other, because there was a moderate heterogeneity (I ^2^  = 49 %) among the studies included. We have no doubt that ligation is better than sclerotherapy, but the advantage of ligation may not be in the bleeding episode, but in the secondary prophylaxis with a faster and safer variceal eradication.

Sclerotherapy and vasoactive drugs combined were superior to sclerotherapy alone in regard to efficacy of bleeding control, overall rebleeding rate, and rebleeding rate from active bleeders in seven, six and four trials, respectively ( [Fig. 5](#FI1465-5){ref-type="fig"} , [Fig. 6](#FI1465-6){ref-type="fig"} , [Fig. 7](#FI1465-7){ref-type="fig"} ). There is a compelling body of evidence that the combination of sclerotherapy and vasoactive drugs is more effective than sclerotherapy alone in hemorrhage control. This meta-analysis confirmed that with a highly significant statistical difference and a low heterogeneity among the studies (7 trials; RR of 1.17; 95 % CI 1.10 -- 1.25; *P*  \< 0.00001; I ^2^  = 25 %). However, there was no difference in respect to mortality in the meta-analysis and in any individual RCT. It is interesting to note that none of these studies were performed in North America (2 European, 1 Brazilian and 4 Asian trials).

Many previous trials and meta-analyses have shown that vasoactive drugs are better than placebo, vasoactive drugs are similar to sclerotherapy, and the combination of vasoactive drugs and sclerotherapy is superior to sclerotherapy alone [@JR1465-25] [@JR1465-47] [@JR1465-48] . A recent meta-analysis [@JR1465-47] even compared therapeutic interventions for AVB with placebo, which has been unacceptable as a treatment option since the early 1990 s.

Another technique that generated a meta-analysis and is not performed anymore is the combination of ligation and sclerotherapy. This therapy was abandoned due to a high incidence of side effects, which was confirmed by our study; nonetheless in this meta-analysis, it was demonstrated to be as effective as ligation alone in bleeding control, rebleeding, and mortality.

In this study, when we analyzed separately active bleeders at the moment of initial endoscopy, use of sclerotherapy with vasoactive drugs was superior to sclerotherapy alone. In 439 patients from four studies, combined therapy reduced rebleeding by 22 % (95 %CI 1.13 -- 1.32) with no heterogeneity. We could not evaluate mortality in this subgroup of patients because the studies, when quoting mortality, did not state this outcome separately (they quoted mortality for both active and non-active bleeders).

Although most studies reported in the literature included patients with recent and ongoing hemorrhage, it should be emphasized that therapies used after bleeding had spontaneously stopped will have their results overestimated. Active bleeding at endoscopy is a well-known risk factor for worse outcomes in patients with variceal as well as non-variceal bleeding [@JR1465-3] . Only six studies of the 36 analyzed included only patients with active variceal bleeding, four of them compared sclerotherapy with the combination of sclerotherapy and octreotide. The other 30 RCTs pooled together the results of the different treatments among active and non-active bleeders at time of endoscopy.

Notwithstanding we have done a meta-analysis with solely two studies comparing ligation plus vasoactive drug versus ligation alone, this is the only available meta-analysis grouping this treatment, which is recommended by AASLD, the American Society of Gastrointestinal Endoscopy (ASGE) and EASL guidelines as the gold standard in management of variceal bleeding (considered as level of evidence 1a, grade A recommendation) [@JR1465-49] [@JR1465-50] [@JR1465-51] . ESGE has no current guideline about this issue. Although that recommendation is routinely used in clinical practice, just two Asian studies evaluated use of ligation plus vasoactive drugs in comparison to ligation alone [@JR1465-20] [@JR1465-40] and another trial compared ligation plus octreotide versus octreotide alone [@JR1465-42] .

In the study by Sung et al., ligation and somatostatin was highly superior to ligation alone in management of variceal bleeding. On the other hand, in the study by Sarin et al., published as an abstract, the combination of ligation and octreotide did not show an advantage over ligation alone. When performing a meta-analysis of both these studies, there was clearly no benefit of combination therapy in terms of rebleeding and mortality. It is important to note that no Western study evaluated the role of ligation plus vasoactive drug in treatment of AVB.

There was no study evaluating use of early TIPS in AVB included in this meta-analysis. The only study using early TIPS selected was excluded because all patients received ligation or sclerotherapy in the first 24 hours, before randomization [@JR1465-52] .

As in every meta-analysis, comparison of studies may have been impaired by differing in-hospital follow-up, which in some studies is evaluated at 5 days and in others at 6 weeks. In this study, those data have been pooled together as overall mortality. Time until rebleeding occurred also varied among studies, ranging from 2 to 5 days and was considered as one sole group. Notably, we excluded patients with hepatocellular carcinoma, who comprise at least one-fifth of bleeders. However, this population of patients has a worse response to any treatment and should be evaluated separately.

Furthermore, we also excluded a few articles that were not published in English due to their unavailability, although their inclusion would not affect the final analysis. Other possible limitations of our study are the unclear risk for concealment of treatment allocation in 18 trials and high risk for blinding of participants/personnel in 10 trials. Meanwhile, the blinding of endoscopists and patients undergoing upper digestive endoscopy is impossible, as in studies involving surgical interventions. Moreover, only nine of 36 studies mentioned conflict of interest. In addition, prediction intervals indicated a significant amount of uncertainty on treatment effect sizes and direction for several of the meta-analytic comparisons performed, which means that many of the research questions addressed are still unanswered. Larger and well-designed trials are needed in this field.

On the other hand, studies using placebo as a treatment were not included because there are well-established treatments available for AVB.

During the last decade, mortality rates with acute variceal bleeds have decreased. Routine medical care varied with respect to use of diagnostic and/or therapeutic endoscopy, balloon tamponade, resuscitation policy, and antibiotic prophylaxis for spontaneous bacterial peritonitis.

Conclusion
==========

In summary, the combination of sclerotherapy and vasoactive drugs is superior to sclerotherapy or vasoactive drugs alone in management of variceal bleeding. Ligation was better than sclerotherapy as a treatment option for variceal bleeding, although heterogeneity of the results may invalidate this assumption. Although society guidelines recommend the combination of endoscopic band ligation and vasoactive medications for treatment of AVB, this statement could not be evidenced in the literature.
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